IGHE and chronic rhinosinusitis with nasal polyps: In previously published RCTs, only the POLY1 and POLY2 (for omalizumab) selected CRSwNP patients with high IgE levels,27 while the remaining trials did not establish corresponding inclusion criteria for type 2 inflammation markers.